Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation

Sponsor
RenJi Hospital
Study ID
NCT06531291
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • Surufatinib — DRUG
    250 mg, po, qd, q3w
  • Serplulimab — DRUG
    200 mg, iv, d1, q3w
  • standard chemotherapy — DRUG
    Decided by PI

Study Details

Currently, there are no standard treatment and relevant exploration for solid tumors patients with NED. The study aims to explore the efficacy and safety of surufatinib combined with serplulimab and standard chemotherapy in the treatment ofadvanced solid tumors with NED, in order to provide a new treatment option for advanced solid tumors patients with NED.

Key Dates

Start date
Aug 10, 2024
Status verified
Jul 2024
Primary completion
Aug 9, 2027
Completion
Aug 9, 2027

Study Design

Enrollment
80 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Surufatinib + serplulimab + standard chemotherapy

Primary Outcome Measure

Progression-Free Survival (PFS) [ Time Frame: approximately 1 years ]

Central Contacts

Related Studies